We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Long-Term Progression and Risk Factors of Diabetic Retinopathy in Type 2 Diabetes: Insights from the Skaraborg Cohort in Sweden

MedXY Editorial Team•Oct 31, 2025•Diabetes & Endocrinology
cohort studyretinopathy đái tháo đườngrisk factorstype 2 diabetes

Introduction

Diabetic retinopathy (DR) remains one of the leading microvascular complications of type 2 diabetes mellitus (T2DM), often impairing vision and potentially leading to blindness. Despite advances in diabetes care, the long-term natural history and risk factors contributing to DR incidence require continuous investigation to refine prevention and treatment strategies. The Skaraborg Diabetes Register study in Sweden prospectively evaluates DR progression up to 24 years following T2DM diagnosis, providing valuable data on cumulative incidence and clinical predictors in a real-world setting.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems ModelingThis study uses longitudinal modeling to compare tirzepatide and semaglutide’s effects on fasting glucose in type 2 diabetes, revealing tirzepatide’s superior control largely due to greater insulin-independent hepatic glucose production supSep 23, 2026Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World StudyEmpagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced abSep 23, 2026GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort StudyA comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.Sep 19, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World Data
Fenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.
Sep 18, 2026
From Mild-to-Moderate to Severe Asthma: Risk Factors and Patient Profiles from the NORDSTAR Cohort and Advances in Severe Asthma ManagementThis review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.Sep 17, 2026
Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative AnalysisAmong type 2 diabetes patients using GLP-1 receptor agonists, oxycodone is linked to higher short-term risks of severe gastrointestinal complications compared to hydrocodone and tramadol, warranting cautious opioid selection in this populatSep 15, 2026